* If you want to update the article please login/register
Our research was conducted to determine if there was a correlation between blood selenium level and NAFLD and advanced liver fibrosis diagnosed by vibration controlled transient elastography in adults in the United States. In males with elevated blood selenium levels, the key inversely relationship between blood selenium and advanced liver fibrosis was discovered in subgroup study. Despite the fact that dietary selenium intake was varied or in different subgroups, the links between blood selenium level and NAFLD/advanced liver fibrosis remained strong. Participants with a lower blood selenium level had a higher incidence of advanced liver fibrosis. An imbalance of selenium homeostasis rather than dietary selenium intake is the root of NAFLD and liver fibrosis in participants with lower blood selenium homeostasis linked to selenium homeostasis.
Source link: https://europepmc.org/article/MED/35975984
The most common liver disease worldwide is non-alcoholic fatty liver disease due to its close association with type 2 diabetes mellitus, obesity, and insulin resistance. Using biochemical surrogate markers, we sought to determine the incidence of liver steatosis and fibrosis among Greenlanders and Danes with T2DM live in Greenland's T2DM. Without a difference in FIB-4 score categories, Greenlanders had lower FIB-4 scores than Danes, 0. 91 vs. 0. 97. Greenlanders with T2DM may be less likely to experience liver disease than Danes with T2DM in Greenland, according to these results, than Danes with T2DM in Greenland.
Source link: https://europepmc.org/article/MED/35440282
Context The use of ethylene glycogenoa is used in traditional medicine to treat hyperlipidaemia. In rats, AMPK mediates the anti-steatotic role of ellagic acid in streptozotocin-induced type 1 diabetes mellitus. Materials and methods Adult male Wistar rats were divided into six groups as control, exposure + EA, control + EA, T1DM + EA, and T1DM + EA+ CC an AMPK inhibitor, T1DM+ EA, T1DM + EA, and T1DM + EA + CC. It also reduced renal and hepatic levels of ROS 62%, MDA 52%, TNF-33. 2%, and IL-6 52%, as well as the NF-55 54%'s nuclear presence, which also increased the nuclear activity of Nrf-2 4-fold and SOD 87%. Discussion and conclusions These results point to the use of EA to treat hepatic disease and non-alcoholic fatty liver disease NAFLD.
Source link: https://europepmc.org/article/MED/34870551
By network pharmacology and molecular docking, as well as cell experiments, it is planned to investigate the therapeutic effects of kaempferol on metabolic associated fatty liver disease. First, use the SwissTargetPrediction database to predict the outcomes of kaempferol, and gather the MAFLD targets from the Disgenet database and the GeneCards database. Kaempferol can reduce cell TG levels, increase lipid deposition, increase the expression of PI3K, AKT, and beclin-1, and beclin-1, as well as reduce the expression of caspase-3 and nuclear factor-kappa B. Cell experiments show that kaempferol can reduce cell TG levels, decrease lipid deposition, decrease lipid deposition, decrease cell proliferation, and inflammation, and reduce inflammation in MAFLD. In the fatty liver cell model, kaempferol can control lipid metabolism, decrease apoptosis, monitor inflammation, and autophagy. It reveals the pharmacological function of kaempferol on MAFLD and provides a natural product candidate for MAFLD therapy.
Source link: https://europepmc.org/article/MED/36083487
To investigate Lizhong's protective effects and molecular mechanisms against non-alcoholic fatty liver disease. Male Wistar rats were given a high-fat diet for four weeks to cause NAFLD, and Gavage administered LZD for four weeks. Using Oil Red O and hematoxylin-eosin staining, Liver pathology was evaluated. Rats with NAFLD had high incidences of hepatic disease and cholesterol deposition, which caused a high incidence of hepatic dysfunction and cholesterol deposition. By activating PPAR-u03b3 and banning DPP4, LZD was able to eliminate NAFLD.
Source link: https://europepmc.org/article/MED/36083485
VBHC is mostly used in common diseases, but there are inherent difficulties in applying VBHC treatments to low volume, high-risk health conditions such as rare disorders, such as inheritable metabolic disorders, persisting. This article summarizes current practices in several academic domains that have value-boosting activities for individuals with liver glycogen storage disorders or fatty acid oxidation disorders and their families.
Source link: https://europepmc.org/article/MED/36088581
A spectrum of liver disease directly related to diabetes, obesity, and metabolic syndrome is represented by non-alcoholic fatty liver disease. Compared to NFD-fed mice, we found that a 6-week HFD significantly increased liver lipid accumulation, as shown by Oil Red O staining and liver triglyceride levels. Importantly, without effecting body weight or glucose levels, PRO20 treatment effectively reduced hepatic lipid accumulation in HFD-fed mice. In comparison to control mice, the percentage of collagen area detected by Sirius Red staining was reduced in PRO20-treated mice in comparison to control mice. In MCD-fed mice compared to controls, significantly reduced levels of liver alanine aminotransferase, an indicator of liver damage. Our findings, taken together, establish the way in which PRR regulates lipid metabolism in the liver and highlight the therapeutic benefits of PRR antagonism for the treatment of liver steatosis and fibrosis in NAFLD.
Source link: https://europepmc.org/article/PPR/PPR542745
The prevalence of non-alcoholic fatty liver disease is on the rise globally, on a path to becoming the most common cause of chronic liver disease. The research involved three arms: placebo, a daily dose of NRPT, and a double dose of NRPT. No significant change was found in the primary endpoint of the study in terms of placebo, relative to placebo. Moreover, a significant decrease in the circulating levels of the inflammatory lipid, ceramide 14:0, was also seen in the NRPT 1X group versus placebo, and this decrease was linked to a decrease in ALT in individuals of this group. This research shows that NRPT at the recommended dose is safe and can reduce indicators of hepatic inflammation in patients with NAFLD.
Source link: https://europepmc.org/article/MED/36082508
Nonalcoholic fatty liver disease is one of the most common chronic liver disease diseases in the world, and it has become a critical public health issue. The best predictive clinical model for NAFLD is based on machine learning algorithms developed by the introduction of machine learning algorithms to determine the most reliable predictive clinical model for NAFLD. The feature selection process is carried out by the PPFS feature selection system, and the final 11 features are preserved. Genetic Algorithm, Neural Network, Random Forest, and Logistic Regression were among the four machine learning algorithms with the highest accuracy, among the ten basic machine learning algorithms that were used. These four algorithms are integrated into the latest Voting algorithm using Ensemble learning's Soft Voting scheme. 1. 67806, 0. 640569, 0. 894010, respectively, to verify the proposed Voting algorithm. It is compared to other ten basic machine learning algorithms. To analyze the new Voting algorithm, it is compared to other ten basic machine learning algorithms.
Source link: https://europepmc.org/article/PPR/PPR542182
Metabolic syndrome is common among renal transplant recipients and is associated with an elevated risk of CVD in those patients. Nonalcoholic fatty liver disease is thought to be the hepatic manifestation of a multi-system disorder affecting CVD and metabolic syndrome. The risk of NAFLD before kidney transplantation was directly and significantly linked to diabetes, male gender, older age, elevated BMI, and elevated triglycerides risk, according to the risk of kidney transplantation. Mean liver enzyme levels were similar in patients with and without NAFLD. And after adjusting to covariables, those with NAFLD before transplantation had a higher risk of new onset diabetes. In addition, kidney transplantation was closely linked to cardiovascular disease following kidney transplantation. The evaluation of kidney transplantation should include sonographic evidence of NAFLD before kidney transplantation, as well as de novo diabetes and cardiovascular mortality following transplantation.
Source link: https://europepmc.org/article/MED/36075195
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions